Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Diabetic Neuropathies
Interventions
DRUG

TAK-128

TAK-128 5 mg, tablets, orally, once daily for up to 6 months.

DRUG

TAK-128

TAK-128 50 mg, tablets, orally, once daily for up to 6 months.

DRUG

TAK-128

TAK-128 100 mg, tablets, orally, once daily for up to 6 months.

DRUG

Placebo

TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.

Trial Locations (48)

Unknown

Mesa

Peoria

Phoenix

Tucson

Little Rock

Huntington Beach

La Jolla

Long Beach

Los Angeles

Northridge

San Francisco

Torrance

Tustin

Aventura

Fort Myers

Hialeah

Miami

Palm Beach Gardens

Plant City

Decatur

Chicago

Louisville

New Orleans

Boston

Ann Arbor

Flint

St Louis

Las Vegas

Elizabeth

New Brunswick

Buffalo

Staten Island

Greenville

Oklahoma City

Morrisville

Dallas

Houston

San Antonio

Norfolk

Tacoma

Calgary

Vancouver

Kingston

North Bay

Sarina

Gatineau

Laval

Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY